AU2202397A - Iib/iiia antagonists co-administered with aspirin and/or heparin - Google Patents

Iib/iiia antagonists co-administered with aspirin and/or heparin

Info

Publication number
AU2202397A
AU2202397A AU22023/97A AU2202397A AU2202397A AU 2202397 A AU2202397 A AU 2202397A AU 22023/97 A AU22023/97 A AU 22023/97A AU 2202397 A AU2202397 A AU 2202397A AU 2202397 A AU2202397 A AU 2202397A
Authority
AU
Australia
Prior art keywords
aspirin
iib
heparin
administered
iiia antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22023/97A
Inventor
Robert J. Anders
Larry P Feigen
Mark N. Milton
Peter F. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU2202397A publication Critical patent/AU2202397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU22023/97A 1996-03-28 1997-03-19 Iib/iiia antagonists co-administered with aspirin and/or heparin Abandoned AU2202397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1435096P 1996-03-28 1996-03-28
US60014350 1996-03-28
PCT/US1997/003735 WO1997035592A1 (en) 1996-03-28 1997-03-19 Iib/iiia antagonists co-administered with aspirin and/or heparin

Publications (1)

Publication Number Publication Date
AU2202397A true AU2202397A (en) 1997-10-17

Family

ID=21764944

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22023/97A Abandoned AU2202397A (en) 1996-03-28 1997-03-19 Iib/iiia antagonists co-administered with aspirin and/or heparin

Country Status (2)

Country Link
AU (1) AU2202397A (en)
WO (1) WO1997035592A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT946185E (en) * 1996-11-27 2005-02-28 Aventis Pharm Prod Inc PHARMACEUTICAL COMPOSITION COMPOSING A COMPOUND WHICH HAS ANTI-XA ACTIVITY AND AN ANTAGONIST COMPOUND OF THE PLAQUETARY AGGREGATION
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6136804A (en) 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
JP2002506024A (en) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド Combination therapy and compositions for acute coronary ischemic syndrome and related conditions
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US6770660B2 (en) 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation

Also Published As

Publication number Publication date
WO1997035592A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
AU694696B2 (en) Sulfonamides and their use
AU1662897A (en) Evaluation and decision making systems
HK1023408A1 (en) Retroreflective article having launderably durable bead-bond
ZA976883B (en) Composite constructions with oriented microstructure.
AU3576197A (en) Penetration-resistant aramid article
AU3846597A (en) Form elements and wall construction with such form elements
AU1991197A (en) Endothelin antagonists with ether-linked groups
HK1025625A1 (en) Barrier unit and articles made therefrom
AU2202397A (en) Iib/iiia antagonists co-administered with aspirin and/or heparin
AU1846397A (en) Prolactin antagonists and uses thereof
AU8095598A (en) Hair-drier or the like
EP0940419A4 (en) Aromatic copolymer and composition containing the same
AU2288097A (en) Laminate
GB9415309D0 (en) Desks and the like
HUP9900068A3 (en) Fuse-switch and/or fuse-disconnector
AU8736498A (en) Improvements in spectacles or the like
AU4396697A (en) Thermoinsulating composite section
AU3856295A (en) Endothelin antagonists
GB2318545B (en) Laminating articles
AU1387197A (en) Security systems
GB9724005D0 (en) Laminate
ZA971617B (en) Panels, boards and the like.
ZA975561B (en) Sulfonamides and their use.
AUPO183796A0 (en) The easy sorter
HU1138U (en) Tablet with polygon form